Kallistatin, a plasma protein, protects against vascular and organ injury. This study is aimed to investigate the role and mechanism of kallistatin in endothelial senescence. 
dysfunction marker plasminogen activator inhibitor-1 (PAI-1) expression. [6] [7] [8] Moreover, cellular senescence is characterized by shortened telomere length or reduced telomerase activity. 9 Oxidative stress and inflammation have been implicated in the ageing process and adversely affect endothelial availability and function. 10, 11 Oxidative stress compromises telomere integrity and nitric oxide (NO) bioavailability to accelerate cellular senescence in endothelial cells. 12 Vascular senescence is also associated with enhanced expression of the inflammatory molecules, vascular cell adhesion molecule-1 (VCAM-1)
and intercellular adhesion molecule-1 (ICAM-1), which leads to augmented adhesion of monocytes into vascular wall, facilitating the ignition and progression of ageing-associated vascular diseases. 13, 14 Therefore, inhibition of oxidative stress and inflammation is of great significance for controlling endothelial senescence.
MicroRNAs (miRNAs) are essential regulators for a plethora of cellular processes. 15 A highly evolutionarily conserved miRNA has been reported to inhibit oxLDL-induced apoptosis of endothelial cells and alleviate atherosclerosis in mice. 16, 17 Let-7g also has the ability to improve multiple endothelial functions by stimulating sirtuin 1 (SIRT1) signalling. 18 Furthermore, miR-34a, a well-recognized tumour suppressor and a senescent inducer, triggers endothelial senescence by directly suppressing the target gene SIRT1. 19 SIRT1, an NAD + -dependent deacetylase and anti-ageing molecule, is decreased in vascular tissue undergoing senescence. 20 Evidence has indicated a positive feedback regulation between SIRT1 and endothelial nitric oxide synthase (eNOS). SIRT1 promotes the expression of eNOS and activates eNOS by its deacetylase activity, while eNOS through NO production stimulates SIRT1 expression. [21] [22] [23] NO produced from eNOS has a wide range of biological properties to maintain vascular homeostasis, including vascular dilation, and inhibition of oxidative stress and inflammation. [24] [25] [26] Therefore, Let7g, miR-34a and antioxidant genes SIRT1 and eNOS are key signalling molecules for regulating endothelial senescence.
Kallistatin was discovered in human plasma as a tissue kallikreinbinding protein and identified as a serine proteinase inhibitor. [27] [28] [29] [30] [31] [32] Kallistatin plays a protective role in vascular and organ injury. 33 Kallistatin gene or protein delivery attenuates vascular and multi-organ injuries by its pleiotropic activities in vasodilation, and inhibition of oxidative stress, inflammation and apoptosis in animal models and cultured cells. [33] [34] [35] [36] [37] [38] [39] [40] Kallistatin inhibits vascular inflammation and oxidative stress by stimulating eNOS expression and activation, and antagonizing tumour necrosis factor (TNF)-a-mediated inflammatory gene expression in endothelial cells. 38, 40, 41 Recently, we showed that kallistatin treatment alleviates endothelial progenitor cell (EPC) senescence, mouse aortic aging and prolonged Caenorhabditis elegans (C. elegans)
lifespan by inhibiting miR-34a and increasing SIRT1 levels. 42 Moreover, plasma kallistatin levels were shown to be positively associated with leucocyte telomere length in young African Americans, implicating the involvement of kallistatin in anti-ageing process. 43 H 2 O 2 is widely used to achieve oxidative stress-induced premature senescence in endothelial cells and fibroblasts. 44, 45 According to previous findings, the dose of H 2 O 2 (100 lmol/L) represents subcytotoxic conditions to induce senescence. 46, 47 In this study, we investigated the role and mechanism of kallistatin in oxidative stress-induced endothe- 
| Telomerase activity assay

| NADPH oxidase activity assay
The enzymatic activity of NADPH oxidase was assessed by a luminescence assay in the presence of lucigenin (250 lmol/L; Sigma) and NADPH (100 lmol/L; Sigma) as described. 50 Fluorescence intensity was continuously monitored for 15 minutes with a TD20/20 luminometer. Protein concentrations were measured by Pierce BCA protein assay kit (Thermo Fisher Scientific, Bremen, Germany). The chemiluminescent signal was normalized by protein concentration.
| Detection of superoxide formation
Cellular superoxide generation was detected using the fluorescent probe 2 0 ,7 0 -dichlorodihydrofluorescein diacetate (DCFH-DA; Sigma) as described. 38 Treated HUVECs in six-well plates were incubated for 
| Quantitation of mRNA by real-time polymerase chain reaction (qRT-PCR)
Total RNA was extracted using Trizol according to manufacturer's instruction. Total RNA was reverse-transcribed using the High-Capacity 
| Generation of endothelium-specific kallistatin knockout mice
Heterozygous kallistatin floxing mice in C57/BL6 strain (male and female, KS 
| Isolation and Identification of mouse lung endothelial cells
Mouse lung endothelial cells were isolated from 8-week-old KS endoÀ/À and WT mice as described. 51 Mice were euthanized by 
| Statistical analysis
| Kallistatin inhibits endothelial senescence and oxidative stress through SIRT1-mediated eNOS pathway
To determine whether the kallistatin-mediated protection against endothelial senescence is associated with antioxidant gene regulation, the effects of kallistatin on the regulation of SIRT1, eNOS, catalase and SOD-2 were determined. Kallistatin treatment not only markedly enhanced SIRT1, eNOS, catalase and SOD-2 expression, but also prevented H 2 O 2 -mediated inhibition of these antioxidant genes ( Figure 3A-D) . Moreover, NAM, a potent inhibitor of SIRT1 activity, blocked kallistatin-stimulated eNOS expression, whereas L-NAME, an NOS inhibitor, had no effect on kallistatin-stimulated SIRT1 expression ( Figure 3E,F 
| Kallistatin by Let-7g up-regulation blocks miR34a-mediated inhibition of SIRT1-eNOS pathway, and reduces endothelial senescence, oxidative stress and inflammation
To illustrate whether kallistatin-mediated inhibition of endothelial senescence was associated with up-regulation of Let-7g, the effect of kallistatin on Let-7g expression was determined. Kallistatin treatment significantly increased Let-7g synthesis, whereas genistein, a tyrosine kinase inhibitor, blocked kallistatin's effect ( Figure 4A ), implicating that kallistatin interacts with a cell surface tyrosine kinase to stimulate Let-7g synthesis. Let-7g inhibitor (Let-7g anti-sense RNA) blocked kallistatin's inhibition of miR-34a synthesis ( Figure 4B ), indicating that kallistatin regulates Let-7g-mediated miR-34a pathway. Conversely, miR-34a mimic had no effect on kallistatin-induced Let-7g expression 
| Identification of kallistatin deficiency in mouse lung endothelial cells
We generated endothelium-specific kallistatin knockout (KS 
| DISCUSSION
This study demonstrates that endogenous kallistatin plays a protective role in endothelial senescence, and kallistatin through a novel mechanism inhibits cellular senescence, oxidative stress and inflammation.
Kallistatin antagonized oxidative stress-induced senescence, as Oxidative stress and inflammation are hallmarks of endothelial senescence. 52, 53 Kallistatin administration has been shown to attenuate vascular injury and organ damage and ageing, in conjunction with reduced oxidative stress and inflammation in animal models with hypertension, arthritis, diabetes and sepsis. [37] [38] [39] [40] 48, 54 In this study, we showed that kallistatin inhibited H 2 O 2 -induced oxidative stress and pro-inflammatory gene expression, including VCAM-1, ICAM-1 and IL-6, in human endothelial cells. Moreover, kallistatin stimulated antioxidant gene expression, including SIRT1, eNOS, catalase and SOD-2.
NO production by eNOS inhibits superoxide formation and inflammation. 25, 26 Catalase, one of SIRT1's downstream antioxidant enzymes, is decreased in H 2 O 2 -induced premature senescence. 55 Human SOD-2 and mouse SOD-1 are antioxidant enzymes and play an important role in the prevention of endothelial senescence and inflammation. 56, 57 Previous reports indicated a reciprocal positive feedback regulation between SIRT1 and eNOS. [21] [22] [23] SIRT1 has been shown to induce eNOS expression and activity, and eNOS through NO formation up- regulates SIRT1 and maintains vascular homoeostasis. [21] [22] [23] [24] Kallistatin was shown to increase SIRT1 and eNOS synthesis in human endothelial cells and EPCs. 42, 58 Moreover, kallistatin treatment increased eNOS activity and NO formation in human endothelial cells. 38 The present study shows that kallistatin stimulates SIRT1-mediated eNOS pathway, as kallistatin-induced eNOS expression was blocked by a SIRT1 inhibitor, but kallistatin-mediated SIRT1 expression was not affected by a NOS inhibitor. Collectively, kallistatin through stimulating SIRT1-mediated eNOS pathway protects against senescence, oxidative stress and inflammation.
Many senescence-associated miRNA signatures have been identified and reported. 59, 60 The present study mainly focused on | 4395 studying the effect of kallistatin on differential regulation of 2 miRNAs, Let-7g and miR-34a in endothelial senescence. Let-7g
was recently recognized as an anti-aging miRNA to improve endothelial functions. 18 Let-7g negatively regulated apoptosis, senescence and inflammation in endothelial cells. [16] [17] [18] Up-regulation of SIRT1 levels was involved in Let-7g -mediated inhibition of endothelial senescence. 18 In this study, we showed that kallistatin increased Let-7g synthesis, and kallistatin, via Let-7g induction, stimulated SIRT1 and eNOS, leading to inhibition of endothelial senescence, oxidative stress and inflammation in endothelial cells. Importantly, kallistatin harbours 2 structural elements, an active site and a heparin-binding domain. [30] [31] [32] Kallistatin's active site is essential for eNOS and SIRT1 expression through interacting with a tyrosine kinase in EPCs and endothelial cells. 42, 58 Kallistatin via its active site stimulates tyrosine kinase-PKC-ERK signalling, leading to the synthesis of suppressor of cytokine signaling-3 (SOCS3), an anti-inflammatory gene in cultured macrophages. 61 It is likely that kallistatin via the active site interacts with tyrosine kinase to stimulate Let-7g synthesis. Moreover, miR-34a-SIRT1 axis has been regarded to be one of critical pathways to regulate endothelial senescence. 19 Our previous study showed that kallistatin reduced EPC senescence and aorta ageing by inhibiting the synthesis of miR-34a, a pro-senescent miRNA. 42 Consistently, the current study indicates that kallistatin treatment inhibited miR-34a and prevented H 2 O 2 -induced miR-34a synthesis in endothelial cells. Importantly, we found that Let-7g is the upstream regulator of miR-34a in response to kallistatin treatment.
These results indicate that kallistatin protects against oxidative stress-induced endothelial senescence by up-regulating Let-7g to inhibit miR-34a-SIRT1-eNOS pathway.
To further investigate the role of endogenous kallistatin in vascular senescence, we generated KS F I G U R E 7 Signalling pathway by which kallistatin inhibits endothelial senescence, oxidative stress and inflammation. Kallistatin through tyrosine kinase stimulates Let-7g synthesis, inhibits miR-34 and up-regulates SIRT1-mediated-eNOS pathway, thereby elevating catalase, SOD-1/2 and NO levels, leading to blockade of H 2 O 2 -modulated ROS formation, p16
INK4a
, PAI-1, VCAM-1, ICAM-1 and IL-6 expression, and telomerase activity in endothelial cells. Genistein, tyrosine kinase inhibitor; NAM, SIRT1 inhibitor; L-NAME, NOS inhibitor reduction in Let-7g, SIRT1, eNOS, catalase and SOD-1. Thus, Let-7g-mediated SIRT1-eNOS pathway is suppressed when kallistatin is deficient. We previously showed that human kallistatin protein treatment reduced vascular senescence and ROS formation, but increased SIRT1 and eNOS levels in aortas of diabetic mice. 42 Moreover, kallistatin gene delivery decreased aortic superoxide levels and glomerular endothelial loss in hypertensive deoxycorticosterone acetate-salt rats. 38 Conversely, kallistatin depletion by neutralizing kallistatin antibody injection exacerbated renal and cardiovascular oxidative stress, inflammation and organ injury in hypertensive rats. 50 These combined findings support the notion that endogenous kallistatin acts as a protective molecule in vascular injury and senescence by stimulating Let-7g, SIRT1 and eNOS, and suppressing miR-34a synthesis.
Overall, this study indicates that kallistatin inhibits cellular senescence, oxidative stress and inflammation by promoting Let-7g-mediated inhibition of miR-34a-SIRT1-eNOS pathway in human endothelial cells. Moreover, endogenous kallistatin plays a protective role in endothelial senescence, oxidative stress and inflammation, as confirmed by kallistatin-deficient mouse endothelial cells. Therefore, kallistatin could potentially be used as a promising new therapeutic strategy for vascular ageing and dysfunction in humans.
